Related references
Note: Only part of the references are listed.Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Herve Tilly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib
Mark Roschewski et al.
BLOOD (2021)
Why R-CHOP plus X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma
Hua-Jay J. Cherng et al.
LEUKEMIA & LYMPHOMA (2021)
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
Grzegorz S. Nowakowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*
Wyndham H. Wilson et al.
LEUKEMIA & LYMPHOMA (2021)
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients
J. J. Eertink et al.
BLOOD ADVANCES (2021)
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
Laetitia Vercellino et al.
BLOOD (2020)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
Qing Deng et al.
NATURE MEDICINE (2020)
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
Nancy L. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL
Andre Goy et al.
BLOOD (2019)
AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R- CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Eliza A. Hawkes et al.
BLOOD (2019)
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Daisuke Ennishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
David Ghez et al.
BLOOD (2018)
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
Matthew J. Maurer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Double hit and double expressors in lymphoma: Definition and treatment
Peter A. Riedell et al.
CANCER (2018)
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
David M. Kurtz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
F. Morschhauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)
Anas Younes et al.
BLOOD (2018)
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Michail S. Lionakis et al.
CANCER CELL (2017)
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
John G. Gribben et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
Idit Sagiv-Barfi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma
Myriam Sasanelli et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Diffuse large B-cell lymphoma-treatment approaches in the molecular era
Mark Roschewski et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma
Tae Min Kim et al.
CANCER (2013)
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
M. Wang et al.
LEUKEMIA (2013)
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yibin Yang et al.
CANCER CELL (2012)
Higher Response to Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Nongerminal Center B-Cell-Like Than in Germinal Center B-Cell-Like Phenotype
Francisco J. Hernandez-Ilizaliturri et al.
CANCER (2011)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin et al.
NATURE GENETICS (2010)
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
Alan G. Ramsay et al.
BLOOD (2009)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Laurie H. Sehn et al.
BLOOD (2007)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells
RE Davis et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Share Paper
